/
Oncology
Bladder Cancer
118
Pipeline Programs↗
293
Active Trials↗
87
Companies Involved↗
Bladder Cancer is a highly competitive landscape with 118 programs across 87 companies. The most active players are Merck & Co., Ferring, Suzhou Forlong Biotechnology Co., Ltd. 31 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical32
Phase 120
Phase 235
Phase 331
Approved
No programs
Analysis
Modality Breakdown
72%
Small molecule
71 of 98 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 98 classified programs, each share of the total. Modality classified for 92% of 118 pipeline programs.
Analysis
Trial Status
673
clinical trials
Completed215 · 32%
Recruiting145 · 22%
Active, not recruiting88 · 13%
Unknown status69 · 10%
Terminated60 · 9%
Not yet recruiting57 · 8%
Other39 · 6%
Clinical Trials
Trial Activity
673 trials
Page 1 of 45
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)